Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was 23.03 DKK, up 1.8% from the year before. Over ten years it grew 13.0% a year on average. The highest annual figure on record is 23.03 DKK in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23.03 DKK | +1.8% |
| FY2024 | Dec 31, 2024 | 22.63 DKK | +21.5% |
| FY2023 | Dec 31, 2023 | 18.62 DKK | +52.4% |
| FY2022 | Dec 31, 2022 | 12.22 DKK | +17.8% |
| FY2021 | Dec 31, 2021 | 10.37 DKK | +15.2% |
| FY2020 | Dec 31, 2020 | 9.01 DKK | +10.0% |
| FY2019 | Dec 31, 2019 | 8.19 DKK | +2.8% |
| FY2018 | Dec 31, 2018 | 7.96 DKK | +3.5% |
| FY2017 | Dec 31, 2017 | 7.70 DKK | +2.9% |
| FY2016 | Dec 31, 2016 | 7.48 DKK | +10.7% |
| FY2015 | Dec 31, 2015 | 6.76 DKK | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?